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Background:  The plasma effect-site equilibrium rate constant (ke0) of propofol has been reported in various 
pharmacodynamic studies; however, it is not desirable to apply ke0 for the link with pharmacokinetic models that 
were separately investigated.  Thus, we titrated ke0 for the pharmacokinetic model, which is known as the multiple 
covariates adjusted model of propofol.
Methods:  Ninety female patients scheduled for gynecologic surgery were randomly assigned to three groups 
targeting different plasma concentrations of 5.4, 8.1, and 10.8 μg/ml.  Target-controlled infusions (TCI) were provided 
by a computer-assisted continuous infusion system.  Time to loss of responsiveness (LOR) was measured by a blind 
investigator; effect-site concentrations (Ce) for LOR were then calculated with simulation of TCI using different ke0s.   
We determined the ke0 minimizing total discrepancy (TD) between the inputted and calculated ke0 from the t1/2ke0s for 
a given probability of LOR of the Ce, and also obtained the ke0 for the minimal TD between the median Ce, which were 
compared to the known ke0.
Results:  Ke0s from these two methods were 0.3692 and 0.3788/min.  Ces for LOR with these ke0s were significantly 
different from those with Schnider’s ke0.
Conclusions:  We proposed a method for titration of the ke0 of propofol.  The ke0s of propofol was lower than 
Schnider’s ke0.  An adequate ke0 for the specific pharmacokinetic model and a certain population would be useful for 
prediction of an accurate Ce, and could be used for calculation of accurate dosing during targeting of the effect site.   
(Korean J Anesthesiol 2010; 58: 231-238)
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Introduction
    Target controlled infusion (TCI) of propofol is known as a 
useful method for maintenance of stable plasma concentration 
within a clinically acceptable range of performance errors. 
Reports from many studies have confirmed the usefulness 
of pharmacokinetic (PK) models that play an important 
role in the TCI system [1,2]. However, we need to determine 
the relationship of effect site concentration and plasma 
concentration in order to describe a time course of the 
concentration of effect site and the effect of a drug.
    In particular, when we begin administration of the drug 
or change the target plasma concentration, the plasma 
concentration quickly achieves the target concentration; 
however, the peak effect of the drug is established slowly. 
This delay (hysteresis) occurs because the action site is the 
effect site, or biophase, not the plasma. This time course of the 
concentration of the effect site and the plasma is explained by 
the plasma and effect site equilibrium rate constant, ke0, which 
is incorporated into the TCI system with various compartmental 
models of propofol. 
    However, coupling of the ke0 from the separate pharma-
codynamic (PD) model to the different PK models or infusion 
schemes is undesirable, and fails to predict the time course 
of the drug effect [3,4]. Struys et al. [5] also revealed that 
the different ke0 for targeting of effect-site concentration of 
propofol predicted different time courses for the effect of 
propofol, as measured by the bispectral index. And Minto 
et al. demonstrated that the time of maximum effect site 
concentration could be useful to combine pharmacokinetics 
and pharmacodynamics [6]. 
    Therefore, in order to optimally link the PK-PD model for 
the TCI system, we attempted to titrate ke0s with two different 
methods in the covariate-adjusted PK model, and compared 
them to the known PD model. 
Materials and Methods
    With approval from the local clinical ethics committee and 
signed informed consent, a total of 90 female patients, ASA 
physical status I, ranging in age from 20-60 yr, who were 
scheduled for gynecologic surgery under general anesthesia 
were entered in this study. Exclusion criteria included body 
weight of less than 70%, or more than 150% of ideal body weight, 
medications for the central nervous system, chronic pain, or 
neurological disorders. In the operating room, an 18-gauge 
catheter was inserted into a large forearm vein for intravenous 
fluid administration and infusion of propofol. Patients received 
glycopyrrolate 0.2 mg intravenously for premedication; 
however, no other sedatives were administrated before and 
during the period of this study. Electrocardiograph, pulse 
oximeter, noninvasive blood pressure monitor, and capnogram 
were applied. Heart rate and blood pressure were monitored 
and recorded every 30 sec for the first 5 min, and then each 
minute, for 10 min. No significant differences with respect to 
age, body weight, height, lean body mass, and body surface area 
were observed between the three groups. Maximal percentages 
of decrease of mean arterial blood pressure and heart rate were 
not significant between the groups (Table 1). 
    Following pre-oxygenation, lidocaine 30 mg was given, and 
propofol (1% Diprivan
Ⓡ, ZENECA Pharmaceuticals, England) 
was administered via a syringe pump (Graseby 3500
Ⓡ, Sims 
Graseby Ltd., Herts, England), which was controlled by the 
STANPUMP through an RS232 interface. We used the three-
compartment mamillary model for propofol, which is known 
as a non-linear mixed effect model that includes age, weight, 
height, lean body mass, and age as covariates [8]. PK parameters 
and their equations with covariates are illustrated in Table 2. 
    Patients were randomly assigned to the three groups; each 
group had a differently targeted plasma concentration (Cp); 
5.4 (Group I), 8.1 (Group II), and 10.8 μg/ml (Group III). A 
plasma concentration of 5.4 μg/ml is known to represent loss of 
consciousness in 95% of subjects [9,10], and 8.1 μg/ml and 10.8 
μg/ml were chosen because they were calculated as the one 
and half, and twice of this Cp95. A propofol filled syringe was 
Table 1. Demographic and Hemodynamic Variables
Group I
(n = 30)
Group II
(n = 30)
Group III
(n = 30)
Age (yr)
Body weight (kg)
Height (cm)
Body surface area (m
2)
Lean body mass (kg)
Maximum % decrease in MAP
Maximum % decrease in HR     
34.7 ± 6.9
56.6 ± 6.9
161.3 ± 4.0
  1.59 ± 0.09
  42.1 ± 3.29
21.6 ± 9.4
11.3 ± 6.9
36.6 ± 8.1
57.4 ± 6.3
158.9 ± 4.8
  1.58 ± 0.09
  41.9 ± 3.10
  23.3 ± 10.2
12.9 ± 8.1
36.2 ± 10.5
58.4 ± 7.9
158.6 ± 6.3
1.58 ± 0.13
41.2 ± 4.50
24.6 ± 12.1
12.0 ± 9.7
Data are reported as mean ± SD. MAP indicates mean arterial 
pressure. HR indicates heart rate. No significant differences between 
groups.
Table 2. Pharmacokinetic Parameters and their Equations with 
Covariates for Target-controlled Infusion of Propofol
Vc (L)
K10 (/min)
K12 (/min)
K13 (/min)
K21 (/min)
K31 (/min)
4.27
Cl1/4.27
Cl2/4.27
0.1958
Cl2/V2
0.0035
Vc indicates the volume of the central compartment. Cl indicates 
clearance. V2 = 18.9 - 0.391 (age - 53), Cl1= 1.89 + 0.0456 (mass - 
77) - 0.0681 (lbm - 59) + 0.0264 (height - 177), Cl2 = 1.29 - 0.024 
(age - 53), Age: age in years, mass: body weight in kilograms, lbm: 
lean body mass in kilograms, height: height in centimeters.233 www.ekja.org
Korean J Anesthesiol Kim, et al.
connected to the 3-channel extension tube with a one-way valve 
to prevent regurgitation of propofol into the intravenous fluid. 
The interval for pump control update and data saving was set 
to 10 seconds, which is the default setting for the STANPUMP. 
To ensure accurate administration of propofol, the patient was 
excluded from the study if any alarm on the TCI device was 
triggered. 
    Once the patient became drowsy, loss of responsiveness was 
assessed by a blind investigator with no knowledge of the target 
concentration; with mild prodding of the shoulders, patients 
were asked to open their eyes every 10 seconds. Any responses 
to these stimuli, such as eye opening, head nodding, or any 
kind of responsive behavior, were defined as ‘responsiveness’; 
and no response was defined as loss of responsiveness (LOR). 
The time from the start of infusion to the point of LOR, and 
the amount of propofol infused until LOR were recorded. The 
study was terminated 10 min after the start of the infusion of 
propofol. After LOR, patients were anesthetized with opiods 
and neuromuscular blocking agents, or underwent tracheal 
intubation, according to their scheduled surgeries. During 
the study, patients received oxygen via facemask. If oxygen 
saturation decreased below 95%, patients were encouraged to 
breathe deeply if they responded to a verbal command; if there 
was no response, manual breathing was supported by use of 
a circle system with oxygen, while maintaining end-tidal CO2 
partial pressure between 35 and 40 mmHg. 
    For analysis of data for a known LOR time, we obtained the 
predicted effect-site concentration for particular values of ke0 by 
re-run of the STANPUMP. First, we executed the STANPUMP, 
inputting data from each subject, such as age, weight, height, 
and sex. Thus, the covariate-adjusted PK parameters were 
obtained, and specific external PK files were made for each 
patient. Each subject file was obtained independently for 
different ke0s. The STANPUMP with command line argument 
of external parameter files was subsequently used to obtain 
predicted effect site concentrations for LOR with different 
ke0. For calculation of effect site concentration, we ran the 
STANPUMP in real mode with the maximum infusion rate 
fixing to 1,200 ml/h. In order to obtain the value of ke0 for PK-
PD coupling, we used two methods for titration, and compared 
them with known ke0.
Titration of ke0 from the link method of ‘Con-
centration-Probability-Time’ (Predicted effect site 
concentration- Probability of LOR- T1/2ke0)
    We investigated the method for calculation of ke0 derived from 
t1/2ke0, which is ln2/ke0, at which the effect-site concentration 
becomes half of the target plasma concentration with a certain 
probability of LOR. When we target a plasma concentration, 
the effect-site concentration rises slowly, and achieves the half 
value of the targeted plasma concentration at half-life of t1/2ke0, 
the three quarters (1/2 + 1/4) at twice of half-lives, and seven-
eighths (1/2 + 1/4 + 1/8) at triple of half-lives (Fig. 1). As we 
targeted 5.4, 8.1, and 10.8 μg/ml of plasma concentration in 
each group, the effect-site concentrations will be 2.7, 4.05, and 
5.4 μg/ml at t1/2ke0, and 4.05, 6.075, and 8.1 μg/ml at two t1/2ke0, 
and 4.425, 7.0875, and 9.45 at triple t1/2ke0. 
    The link of the ‘concentration’ and ‘probability’ were obtained 
with 9 different ke0s (ranging 0.2-0.6 with 0.05 intervals). Each 
analysis proceeded separately, and probabilities of 0.1-0.99 at 
0.1-0.5 intervals were attained. Probabilities of LOR at effect-
site concentrations that were half, three quarters, or seven-
eighths of the target plasma concentration were obtained from 
probit regression analysis. The link of times to the probability 
of LOR in each group was obtained from the probit regression 
analysis curve. These regression curves were used for the link 
of the ‘probability’ to ‘time’ (one, two, and three times of the 
t1/2ke0). Times associated with a given probability of a certain 
effect-site concentration of the target concentrations were 
then matched to t1/2ke0 in each group. If the given effect site 
concentrations were the value of the 3/4 or 7/8 target plasma 
concentration, the associated times were divided by 2 or 3, and 
the ke0 of each group was calculated from t1/2ke0 (= ln2/ke0).
    While ke0 changed, the ke0 that we inputted and the calculated 
ke0 from this link of ‘concentration-probability-time’ showed 
a discrepancy. Therefore, we sought to determine a ke0 value 
that could minimize the total discrepancy (TD) between the 
inputted ke0 and the calculated ke0. Total discrepancy for each 
ke0 was the summation of squared differences of the applied ke0, 
and the calculated ke0 for a certain probability of the given effect 
Fig. 1. Example of the time course of the plasma (dotted line) and 
effect site (solid line) concentrations of propofol targeted to 8.1 μg/
ml of plasma concentration of propofol. Dash-dot line indicates that 
the predicted effect-site concentration achieves half (4.05 μg/ml) of 
the target plasma concentration (Cp) at one t1/2ke0, three quarter (6.08 
μg/ml) of Cp at two times of t1/2ke0, and seven eighth (7.09 μg/ml) of 
Cp at three times of t1/2ke0.234 www.ekja.org
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site concentration in each group, and was expressed as follows:
in which Ike0 was the inputted ke0 for the regression curve of 
the probability and effect-site concentration, and Cke0-ij is the 
calculated ke0 of the effect-site concentration at i times of t1/2ke0 
in the j
th group for the link of time-concentration-probability; 
and N is the number of the available calculations used for each 
ke0. The ke0 for minimal TD was calculated by the nonlinear 
regression method with curve fitting of a polynominal quadratic 
equation (Sigmaplot 2001
Ⓡ, 7.0 edition, SPSS Inc.). The 
following equation was used:
   TD = y0 + B*ke0 + A*ke0
2
in which y0, B, and A were the coefficients for the quadratic 
equation. The values of these coefficients and standard errors 
were analyzed, and ‘-A/2B’ determined the final estimation of 
ke0.
Titration of ke0 for the minimal discrepancy between 
the median effect site concentrations of each group
    This analysis was based on the assumption that the effect site 
concentration of a drug for a specific PD profile would be the 
same, even though subjects received different target plasma 
concentrations. Likewise, patients would be unresponsive at 
certain stimuli at the same effect site concentration. Thus, we 
compared the median effect site concentrations of propofol 
with nine different ke0s (ranging 0.2-0.6 with 0.05 intervals) 
that could minimize discrepancy between the groups. The 
predicted effect site concentration was obtained by a dry run 
of the STANPUMP with a previously described patient specific 
external PK file. Total discrepancies (TD) for each ke0 were 
obtained using the following equation:
TD (ke0) = [(Ce1 - Ce2)
2 + (Ce2  - Ce3)
2 + (Ce3 - Ce1)
2]
1/2
where Ce1, Ce2, and Ce3 were the median predicted effect-site 
concentrations for LOR of the 5.4, 8.1, and 10.8 μg/ml targeted 
groups. The ke0 for minimal TD was calculated using the 
nonlinear regression method described above.
Comparison with Schnider’s PD model
    The ke0s obtained from our two analytical methods were 
compared with Schnider’s pharmacodynamics [7]. Using 
a previously described simulation of the STANPUMP, the 
predicted effect site concentrations for each subject (n = 90) 
from these three ke0 were obtained all over again. We compared 
mean effect site concentrations for LOR, and also found effect 
site concentrations of propofol that could represent LOR in 
50% (Ce50) and 95% (Ce95) of subjects for each ke0s. The times to 
peak effect of the TCI system for these ke0s were furthermore 
calculated using the STANPUMP.
    Comparisons of demographic and hemodynamic variables, 
observations of LOR, and mean effect site concentrations were 
performed using analysis of variance with post-hoc multiple 
comparison at a P < 0.05 level of significance. Unless stated 
otherwise, data are presented as mean ± SD. Regression 
between time, probability, and concentration were performed 
using probit regression analysis (SPSS, version 10.0.1, SPSS 
Inc.), and were expressed with 95% confidence intervals.
Results
    Times to LOR for each group are illustrated in Fig. 2. Obser-
vations made at the time of LOR are shown in Table 3. Patients 
lost responsiveness more rapidly when the TCI device was 
targeted at higher plasma concentrations. However, less 
propofol was administered until LOR in patients targeted at 8.1 
Table 3. Observations at Loss of Responsiveness (LOR)
Group I
(n = 30)
Group II
(n = 30)
Group III
(n = 30)
Median LOR (sec)
Mean LOR (sec)
Propofol infused until
  LOR (mg)
320
325.3 ± 80.6*
 138.1 ± 28.05
‡
160
158.3 ± 35.4
†
118.5 ± 18.74
90
88.7 ± 26.9
107.3 ± 20.83
Data are reported as mean ± SD. *Significantly different with respect 
to Group II and III (P < 0.05). 
†Significantly different with respect 
to Group I and III (P < 0.05). 
‡Significantly different with respect to 
Group II and III (P < 0.05).
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Fig. 2. Scatter plots (v) and means (SD) showing the time to loss 
of responsiveness (LOR) of patients targeted to 5.4 (Group I), 8.1 
(Group II), and 10.8 μg/ml (Group III) of the plasma concentration 
of propofol during induction of anesthesia. 235 www.ekja.org
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and 10.8 μg/ml than in those targeted at 5.4 μg/ml of plasma 
concentration. 
    An example of the method for the link of ‘Concentration-
Probability-Time’ for a particular ke0 (0.4/min) in patients 
who received propofol to 8.1 μg/ml of the target plasma 
concentration is shown in Fig. 3. Calculated ke0s (Cke0) for a 
differently inputted ke0 (Ike0) and the probabilities (PLOR) of 
LOR at given effect site concentrations of 1/2, 3/4, and 7/8 of 
Fig. 3. Example of two probit regression curves gives the link of concentration to probability (PLOR) of loss of responsiveness (LOR), and time. 
(Left) Graph shows the probability of LOR for the predicted effect site concentration (Ce) when a certain plasma effect-site equilibrium rate 
constant (ke0 = 0.4/min) was inputted. (Right) Graph shows the time for probability of LOR when propofol was administered at 8.1 μg/ml of 
the target plasma concentration. (Lower) Dotted lines show that 20% of subjects represented LOR at 4.05 μg/ml (half value of target plasma 
concentration) of Ce, and the time for 20% LOR in this group was 120 sec, which was the t1/2ke0. Thus, the calculated ke0 was 0.3442/min. (Upper) 
Dotted lines show that 95% of subjects represented LOR at 6.07 μg/ml (3/4 of the target plasma concentration) of Ce, and that the time for 95% 
LOR was 220 sec, which was two times of t1/2ke0. Thus, the calculated ke0 was 0.3853/min. 
Table 4. Calculated Plasma Effect-site Equilibrium Rate Constant (Cke0) for Differently Inputted ke0 (Ike0) and the Probability of LOR (PLOR) at a 
given Effect-Site Concentration of 1/2, 3/4, and 7/8 of the Target Plasma Concentration (Cp)
Ike0 (/min) 0.30 0.35 0.40 0.45 0.50 0.55 0.60
Group I
    1/2 × Cp 
    3/4 × Cp 
    7/8 × Cp
Group II
    1/2 × Cp
    3/4 × Cp
    7/8 × Cp
Group III
    1/2 × Cp
    3/4 × Cp
    7/8 × Cp
N
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
PLOR
Cke0
0.07
0.2079
0.55
0.2535
0.80
0.3248
0.55
0.2635
NA
-
NA
-
0.95
0.3245
NA
-
NA
-
5
0.02
0.2701
0.35
0.2890
0.65
0.3575
0.35
0.3010
0.98
0.3593
NA
-
0.91
0.3461
NA
-
NA
-
6
NA
-
0.20
0.3309
0.50
0.3922
0.20
0.3442
0.95
0.3853
NA
-
0.80
0.3887
NA
-
NA
-
5
NA
-
0.15
0.3554
0.40
0.4187
0.15
0.3667
0.90
0.4096
NA
-
0.70
0.4217
NA
-
NA
-
5
NA
-
0.09
0.3930
0.30
0.4510
0.09
0.4086
0.83
0.4319
0.98
0.5388
0.58
0.4620
NA
-
NA
-
6
NA
-
0.07
0.4141
0.28
0.4637
0.07
0.4304
0.75
0.4653
0.96
0.5676
0.50
0.4906
NA
-
NA 
-
6
NA
-
0.06
0.4274
0.18
0.513
0.06
0.4437
0.70
0.4807
0.92
0.6037
0.40
0.5325
NA
-
NA
-
6
LOR indicates loss of responsiveness. NA indicates ‘not available’ . N is the number of available calculations used for each ke0. 236 www.ekja.org
Ke0 of propofol for PK-PD model Vol. 58, No. 3, March 2010
the target plasma concentration (Cp) in each group are listed 
in Table 4. Because the effect site concentration of highest 
probability (PLOR = 0.99) was lower than predicted in group II 
and III, times to the predicted effect site concentration could 
not be calculated when we applied ke0 for 0.2 and 0.25/min. 
Likewise the Cke0 could not be calculated when the predicted 
concentration was lower than 1% of probability or higher than 
100% of probability. These unavailable data were expressed 
as ‘NA’ in Table 4. TD of the inputted ke0 and the calculated 
ke0 for different ke0 is shown in Fig. 4. Coefficients ± SE for 
the regression curve were 0.0310 ± 0.0043 for y0, -0.158 ± 
0.0199 for A, and 0.2145 ± 0.0220 for B (R
2 = 0.9906, P < 0.001), 
respectively. The ke0 for the minimal TD was 0.3692/min. TD of 
the median predicted effect site concentration for different ke0 
is shown in Fig. 5. The coefficients ± SE for the regression curve 
were 2.6624 ± 0.1750 for y0, -9.4815 ± 0.9360 for A, and 12.5145 
± 1.1584 for B (R
2 = 0.9568, P < 0.001), respectively. The ke0 for 
the minimal TD was 0.3788/min. 
    The TCI system from the PD model of Schnider et al. predicted 
higher effect site concentrations for LOR than those obtained 
in our study. Effect site concentrations were not significantly 
different between our two results for ke0. Predicted effect site 
concentrations of LOR in 50% and 95% of subjects for three 
different ke0s are shown in Table 5. Time to peak effect from 
Schnider’ PD was nearly identical with that of our results. 
Discussion
    The aim of this study was to titrate the ke0 of propofol for the 
optimal link of pharmacodynamics to a specific PK model 
for the TCI. This method of link between ‘Concentration-
Probability-Time’ could provide the optimal ke0 for the PK-PD 
model of propofol. A similar result was also obtained from the 
method for the minimal discrepancy between the median effect 
site concentrations; however, our results were lower than the 
previously published value of ke0. 
    Schnider et al. [7,8] reported that the ke0 of propofol was 
0.316/min using the ‘connect-the dots’ model of plasma 
concentration, and 0.456/min using the covariate-adjusted PK 
set. Results of this study were different from those of Schnider’s 
ke0, and the calculated effect-site concentration of LOR from 
Schnider’s ke0 was significantly higher than the effect-site 
concentration from our results, and the times to peak effect 
was slightly longer. The reasons for these differences could 
Fig. 4. Scatter plot shows the ke0 and the total discrepancy (TD) of 
the squared difference of the inputted plasma effect-site equili-
brium rate constant (ke0) and the calculated ke0 from the link of 
concentration of propofol, probability of loss of responsiveness, and 
t1/2ke0 for the target controlled infusion with the non-linear mixed 
effect pharmacokinetic model of propofol. The quadratic curve 
shows the regression of the ke0 and total discrepancy; the ke0 for the 
minimal TD was 0.3692 /min (arrow end of dotted line).
Fig. 5. Scatter plot shows the plasma effect-site equilibrium rate 
constant (ke0) and the total discrepancy (TD) of the squared diffe-
rence of the median predicted effect site concentration between the 
three groups for the target controlled infusion with the non-linear 
mixed effect pharmacokinetic model of propofol. The quadratic 
curve shows the regression of the ke0 and total discrepancy; the ke0 
for the minimal TD was 0.3788/min (arrow end of dotted line). 
Table 5. Mean Predicted Concentrations (Ce) of Effect-site of Loss of 
Responsiveness (LOR) and predicted Effect-site Concentrations of 
LOR in 50% (Ce50) and 95% (Ce95) of Patients, and Time to Peak Effect 
and t1/2ke0
Ke0 (/min) 0.3692* 0.3788* 0.456
†
Ce (μg/ml )
Ce50 (g/ml)
  (95% CI)
Ce95 (g/ml)
  (95% CI)
Time to peak effect (min)
  (range)
T1/2ke0 (min)
4.50 ± 0.84
4.52
(4.46-4.57)
5.82
(5.70-5.97)
1.72
(1.70-1.75)
1.87
4.57 ± 0.84
4.56
(4.49-4.63)
5.86
(5.73-6.03)
1.71
(1.68-1.73)
1.83
  5.08 ± 0.83
‡
5.04
(4.98-5.09)
6.35
(6.22-6.49)
  1.69
†
-
1.52
Ke0 indicates plasma effect-site equilibrium rate constant. *Values 
from the results of this study. 
†Values from the study of Schnider et 
al. [7]. 
‡Significantly different from the Ces of this study (P < 0.001). 237 www.ekja.org
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be attributed to the following: First, monitoring of the central 
nervous system is a continuous measure of the drug effect 
of propofol. However, our study used LOR as the primary 
measure of the time course of the drug effect. Even though this 
measurement is useful in routine clinical settings, it required 
10 second intervals. Therefore, it could be possible that some 
subjects could have lost responsiveness prior to assessment of 
the pharmacodynamic profile. As a result, the regression curve 
for ‘concentration-probability’ could be shifted to the right side; 
however, the regression curve for ‘probability-time’ also shifted 
to the right side. These consequences would be reflected in the 
influence on the final outcome of the ke0. Second, the influence 
of gender on pharmacokinetics and pharmacodynamics could 
be considered as a significant cause for the difference of ke0. Gan 
et al. [9] reported that gender proved to be a highly significant 
independent predictor for recovery time, and that women woke 
significantly faster than men. All subjects in our study were 
female. If gender differences in the sensitivity of propofol at the 
effect site exist, the ke0 could be different. Thus, gender might 
be considered as one of the important variables in PD studies 
of propofol, even though the gender difference with regard to 
pharmacokinetics could not be completely excluded.
    The TCI system from our results predicted effect site 
concentrations that were lower than those from Schnider’s ke0 
by about 0.5 μg/ml. Similarly, the Ce50 and Ce95 from our results 
appeared to be different from that of Schnider’s ke0; however, 
these differences are believed to originate from the different 
value of ke0.
    Vuyk et al. [10] showed that the Cp50 and Cp95 of propofol for 
loss of eye reflexes were 2.07 and 2.78 μg/ml and for loss of 
consciousness were 3.40, 4.34 μg/ml. Kazama et al. [11] also 
found that the plasma concentration for loss of response to 
verbal command in 50% and 95% were 4.4 and 7.8 μg/ml. In a 
study of the drug interaction of propofol and fentanyl, Smith 
et al. [12] showed that Cp50 and Cp95 for propofol alone were 3.3 
and 5.4 μg/ml. The differing results of these concentrations 
would also be due to differences in the study population, 
methodology, and PK models. A post-hoc power analysis 
conducted for determination of power revealed that total 
sample sizes of 90 and 90 achieve 93.1% power for detection of a 
difference of -0.51 between the null hypothesis stating that both 
means are 4.57 and the alternative hypothesis stating that the 
mean of effect-site concentration from 0.456/min of ke0 is 5.08, 
with estimated group standard deviations of 0.84 and 0.83, and 
with a significance level (alpha) of 0.01, using a two-sided two-
sample t-test.
    Lim [13] demonstrated a novel method of deriving the ke0 
for propofol in the conventional three-compartment model of 
Marsh et al. [14], and found that the value of ke0 was 0.80/min. 
This study compared the three infusion patterns without using 
the TCI system, and the methodology was quite similar to the 
second method used in this study. Our previous research [15] 
also confirmed that the ke0 of propofol was 0.77/min for the 
minimal difference of the median effect site concentration in 
the PK model of Gepts et al. [16]. 
    We did not use the simulation mode of the STANPUMP; we 
used the real mode with an empty syringe for a dry run to obtain 
the predicted effect site concentration for a particular ke0 in 
each patient. In the simulation mode of the STANPUMP, initial 
maximum flow rate was higher than in the real mode (1,200 ml/h), 
and the amount of propofol until LOR was different from the 
actual amount administrated during the study. Therefore, effect-
site concentrations were calculated differently. For example, 
if we simulate the predicted effect site concentration of one 
patient (e.g. female, age 34 years, weight 55 kg, height 150 cm, 
ke0 0.4/min) targeted to 10.8 μg/ml of plasma concentration, and 
time to LOR is 80 sec, the pump speed is 1,798 ml/h during the 
first 10 sec, and then decreases to 259 ml/h, and the predicted 
effect site concentration is 4.25 μg/ml, and 98 mg of propofol is 
infused at LOR in simulation mode. However if we run in real 
mode by dry run, the predicted effect site concentration will 
be 4.09 μg/ml at LOR. This overestimation of the concentration 
will shift the ‘concentration-probability’ curve to the right side. 
Eventually the t1/2ke0 decreases, and the calculated ke0 increases.
    The ke0 plays an important role in the TCI system. When 
we target the plasma concentration, the time course of the 
effect site concentration is the predicted convolution of 
the concentration of plasma over time for ke0e
-ke0t, with the 
disposition function of the effect site [17,18]. If inadequate 
values of ke0 were applied, the effect site concentrations 
would be predicted as either higher or lower than the ‘real’ 
concentration of the effect site. However, this could occasionally 
be just a passive reference guideline on the time course of 
the effect of the drug, because even though we apply a higher 
value of ke0, if we wait for a longer period of time (4-5 times of 
t1/2ke0 for the smallest possible ke0), the plasma and the effect 
site concentration will reach equilibrium in the end. However, 
when we target the effect site concentration, ke0 plays a more 
important role by determining the amount of drug rapidly 
achieving the targeted effect site concentration of the drug. If 
we applied a lower value than the ‘real’ ke0, more amount of 
drug would be administrated; hence, overshooting the effect 
of the drug could occur, and the likelihood of side effects 
would increase. The computer simulation shown in Table 6 
demonstrates the different doses and patterns of infusion of 
propofol targeted to 5.4 μg/ml of the effect site concentration 
when a different ke0 is applied during TCI. Initial bolus dose 
for rapid achievement of the targeted effect site concentration 
increased as we applied smaller values of ke0. Therefore, titration 
of the optimal ke0 for the adequate link of pharmacodynamics 238 www.ekja.org
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and pharmacokinetics during TCI is essential. 
    Techniques used in our proposed method are not so complex 
or integrated as those measuring EEG or bispectral index, 
and could be conducted in routine clinical settings without 
increased cost. If we make out the exact relationship between 
the effect-site concentration and the probability of a certain PD 
endpoint, the ke0 for any population could be easily calculated. 
Moreover, the first method could be used for investigation 
of ke0 for a wide range of possibilities, and for the effect site 
concentration for various levels of sedation during the process 
of analysis. However, in order to confirm the validity of the ke0 
from this study, we should assess the TCI of effect site targeting 
with the ke0 under monitoring of the central nervous system. 
Doufas et al. [19] tested the TCI of propofol with the PK model 
of Schnider with 0.456/min of ke0 for the targeting of the effect 
site concentration, and demonstrated the validity and stability 
of this constant during mild to moderate sedation. 
    We proposed two methods of analysis for titration of the ke0 
of propofol. Optimal ke0 should be obtained for the proper 
link of pharmacokinetics and pharmacodynamics during TCI. 
Adequate ke0 for a specific PK model will predict an accurate 
time course of concentration, and will be used for better control 
of the effect site concentration during targeting of the effect site.
References
1. Coetzee JF, Glen JB, Wium CA, Boshoff L. Pharmacokinetic model 
selection for target controlled infusions of propofol: assessment of 
three parameter sets. Anesthesiology 1995; 82:1328-45.
2. Vuyk J, Engbers FH, Burm AG, Vletter AA, Bovill JG. Performance 
of computer-controlled infusion of propofol: an evaluation of five 
pharmacokinetic parameter sets. Anesth Analg 1995; 81: 1275-82.
3. Gentry WB, Krejcie TC, Henthorn TK, Shanks CA, Howard KA, 
Gupta DK, et al. Effect of infusion rate on thiopental dose-response 
relationships: assessment of a pharmacokinetic-pharmacodynamic 
model. Anesthesiology 1994; 81: 316-24.
4. Wakeling HG, Zimmerman JB, Howell S, Glass PS. Targeting effect 
compartment or central compartment concentration of propofol: 
what predicts loss of consciousness? Anesthesiology 1999; 90: 92-7.
5. Struys MM, De Smet T, Depoorter B, Versichelen LF, Mortier EP, 
Dumortier FJ, et al. Comparison of plasma compartment versus 
two methods for effect compartment-controlled target-controlled 
infusion for propofol. Anesthesiology 2000; 92: 399-406.
6. Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL. 
Using the time of maximum effect site concentration to combine 
pharmacokinetics and pharmacodynamics. Anesthesiology 2003; 
99: 324-33. 
7. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen 
C, Goodale DB, et al. The influence of age on propofol 
pharmacodynamics. Anesthesiology 1999; 90: 1502-16.
8. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, 
Shafer SL, et al. The influence of method of administration and 
covariates on the pharmacokinetics of propofol in adult volunteers. 
Anesthesiology 1998; 88: 1170-82. 
9. Gan TJ, Glass PS, Sigl J, Sebel P, Payne F, Rosow C, et al. Women 
emerge from general anesthesia with propofol/alfentanil/nitrous 
oxide faster than men. Anesthesiology 1999; 90: 1283-7.
10. Vuyk J, Engbers FH, Lemmens HJ, Burm AG, Vletter AA, Gladines 
MP, et al. Pharmacodynamics of propofol in female patients. 
Anesthesiology 1992; 77: 3-9.
11. Kazama T, Ikeda K, Morita K. Reduction of fentanyl of the Cp50 
values of propofol and hemodynamic responses to various noxious 
stimuli. Anesthesiology 1997; 87: 213-27. 
12. Smith C, McEwan AI, Jhaveri R, Wilkinson M, Goodman D, Smith 
LR, et al. The interaction of fentanyl on the Cp50 of propofol for loss 
of consciousness and skin incision. Anesthesiology 1994; 81: 820-8.
13. Lim TA. A novel method of deriving the effect compartment 
equilibrium rate constant for propofol. Br J Anaesth 2003; 91: 730-2. 
14. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model 
driven infusion of propofol in children. Br J Anaesth 1991; 67: 41-8. 
15. Kim JH, Min SK, Cho WD, Moon BK, Lee YJ, Kim JS. Titration of the 
microconstant of effect-site for the target-controlled infusion of 
propofol. Intraven Anesthesia 2002; 6: 181-6.
16. Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol 
administered as constant rate intravenous infusions in humans. 
Anesth Analg 1987; 66: 1256-63.
17. Hull CJ, Van Beem HD, McLeod K, Sibbald A, Watshon MJ. A 
pharmacodynamic model for pancuronium. Br J Anaesth 1978; 50: 
1113-23. 
18. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous 
modeling of pharmacokinetics and pharmacodynamics: 
application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-
71. 
19. Doufas AG, Bakhshandeh M, Bjorksten AR, Greif R, Sessler DI. A 
new system to target the effect-site during propofol sedation. Acta 
Anaesthesiol Scand 2003; 47: 944-50.
Table 6. Simulation Showing Different Bolus Doses and Infusion 
Rate of Propofol Targeting to 5.4 µg/min of the Effect-site Concen-
tration when Different Plasma Effect-site Equilibrium Rate Con-
stants (ke0) are Applied During TCI (Simulation for a Female Subject, 
35 years, Body Weight 56 kg, Height 166 cm)
Ke0 (/min) 0.2 0.3692 0.456
Initial bolus (mg/kg)
Time to peak effect (sec)
Starting continuous infusion rate 
  (µg/kg/min)
2.49
121
294.2
1.61
95
315.4
1.25
90
265.3